These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
825 related articles for article (PubMed ID: 20405290)
1. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Kühne T; Imbach P Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290 [TBL] [Abstract][Full Text] [Related]
3. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Garnock-Jones KP Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480 [TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
5. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973 [TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Zhang Y; Kolesar JM Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810 [TBL] [Abstract][Full Text] [Related]
7. Moving towards a new era in the management of chronic immune thrombocytopenia. Wadenvik H; Olsson B Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846 [TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era. Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624 [TBL] [Abstract][Full Text] [Related]
10. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608 [TBL] [Abstract][Full Text] [Related]
11. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study. Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869 [TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Atkinson K Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797 [TBL] [Abstract][Full Text] [Related]
13. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Kuter DJ Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660 [TBL] [Abstract][Full Text] [Related]
15. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia. Panzer S Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229 [TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Al-Samkari H; Kuter DJ Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942 [TBL] [Abstract][Full Text] [Related]
17. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Stasi R; Evangelista ML; Amadori S Drugs; 2008; 68(7):901-12. PubMed ID: 18457458 [TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028 [TBL] [Abstract][Full Text] [Related]
19. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654 [TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]